Back to Rare Disease
This trial is complete. It is no longer accepting participants. Results may be available on ClinicalTrials.gov.

NCT01894165

NCT01894165
Completed Phase 1

Who may be able to join

Who might be able to join this trial:

  • You are between 18 and 60 years old and weigh between 55 kg (about 121 lbs) and 100 kg (about 220 lbs)
  • You are willing and able to sign a written consent form agreeing to take part
  • If you are a woman who could become pregnant, you must have a negative pregnancy test and be using an approved form of birth control for the whole study
  • If you are a man, you must be using a barrier method of contraception (such as a condom) during the study

Who may not be able to join:

  • You are pregnant or currently breastfeeding
  • You have an abnormal heart rhythm measurement (called QTc interval) or a family history of a condition called Long QT Syndrome (confirm with trial site)
  • Your kidneys are not filtering blood at a sufficient rate (confirm with trial site)
  • Your blood test results or liver enzyme levels fall outside an acceptable range (confirm with trial site)
  • You have HIV, Hepatitis B, or Hepatitis C
  • You have another active infection in your body or any form of cancer
  • You have taken part in another clinical drug trial within the last 60 days
  • You have had major surgery within the last 90 days
  • You have a history of illegal drug use or heavy alcohol dependence within the past 2 years
  • You test positive for drugs or alcohol on a screening test
  • You have drunk alcohol within 48 hours before the study medication is given
  • You have recently donated or lost a significant amount of blood (approximately one pint or more)
  • You are currently taking hormone replacement therapy or certain prescription medications (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Trial details

Status
Completed
Phase
Phase 1
Sponsor
Origin Biosciences
Registry
clinicaltrials_gov
Start date
1 June 2013
Est. completion
1 September 2013

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Safety and tolerability of single dose of ALXN1101 in healthy adult subjects

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

View original record on ClinicalTrials.gov